LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage

Sheerien Rajput; Khurram Minhas; Iqbal Azam; Usman Shaikh; Azhar Hussain; El Nasir Lalani

doi:10.1080/10428194.2018.1563697

LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage

Sheerien Rajput, Khurram Minhas, Iqbal Azam, Usman Shaikh, Azhar Hussain, El Nasir Lalani

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a heterogeneous disease of the bone marrow (BM). Its association with Epstein–Barr virus (EBV) remains enigmatic. Aim of our study was to determine expression of latent membrane protein 1 (LMP1), aldehyde dehydrogenase 1 (ALDH1), CD117 and their association with 5-year survival in MM patients. Seven percent of cases expressed LMP1 in MM cells with no association with survival. Whereas, LMP1 expression in CD138- non-neoplastic cells was observed in 80% of the cases, conferring a survival advantage of 1.75 years (mean 3.75 ± 0.28, 95% CI 3.19–4.3). LMP1 in CD138- non-neoplastic cells was associated with CD117 expression in MM cells. Combinatorial analysis of LMP1 and CD117 stratified patients into good prognostic group LMP1+/CD117- (mean survival 4.16 ± 0.39 years) and a worst prognostic group; LMP1-/CD117+ (mean survival 1.02 ± 0.29 years). Our study showed that LMP1 expression in CD138- non-neoplastic cells of BM in MM patients confers a survival advantage.

Original language	English
Pages (from-to)	1991-2001
Number of pages	11
Journal	Leukemia and Lymphoma
Volume	60
Issue number	8
DOIs	https://doi.org/10.1080/10428194.2018.1563697
Publication status	Published - 3 Jul 2019

Keywords

LMP1
multiple myeloma
stem cell markers

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2018.1563697

Cite this

@article{a24c0e07b78448a0935e4d8328f040db,

title = "LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage",

abstract = "Multiple myeloma (MM) is a heterogeneous disease of the bone marrow (BM). Its association with Epstein–Barr virus (EBV) remains enigmatic. Aim of our study was to determine expression of latent membrane protein 1 (LMP1), aldehyde dehydrogenase 1 (ALDH1), CD117 and their association with 5-year survival in MM patients. Seven percent of cases expressed LMP1 in MM cells with no association with survival. Whereas, LMP1 expression in CD138- non-neoplastic cells was observed in 80% of the cases, conferring a survival advantage of 1.75 years (mean 3.75 ± 0.28, 95% CI 3.19–4.3). LMP1 in CD138- non-neoplastic cells was associated with CD117 expression in MM cells. Combinatorial analysis of LMP1 and CD117 stratified patients into good prognostic group LMP1+/CD117- (mean survival 4.16 ± 0.39 years) and a worst prognostic group; LMP1-/CD117+ (mean survival 1.02 ± 0.29 years). Our study showed that LMP1 expression in CD138- non-neoplastic cells of BM in MM patients confers a survival advantage.",

keywords = "LMP1, multiple myeloma, stem cell markers",

author = "Sheerien Rajput and Khurram Minhas and Iqbal Azam and Usman Shaikh and Azhar Hussain and Lalani, {El Nasir}",

note = "Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2019",

month = jul,

day = "3",

doi = "10.1080/10428194.2018.1563697",

language = "English",

volume = "60",

pages = "1991--2001",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage

AU - Rajput, Sheerien

AU - Minhas, Khurram

AU - Azam, Iqbal

AU - Shaikh, Usman

AU - Hussain, Azhar

AU - Lalani, El Nasir

PY - 2019/7/3

Y1 - 2019/7/3

N2 - Multiple myeloma (MM) is a heterogeneous disease of the bone marrow (BM). Its association with Epstein–Barr virus (EBV) remains enigmatic. Aim of our study was to determine expression of latent membrane protein 1 (LMP1), aldehyde dehydrogenase 1 (ALDH1), CD117 and their association with 5-year survival in MM patients. Seven percent of cases expressed LMP1 in MM cells with no association with survival. Whereas, LMP1 expression in CD138- non-neoplastic cells was observed in 80% of the cases, conferring a survival advantage of 1.75 years (mean 3.75 ± 0.28, 95% CI 3.19–4.3). LMP1 in CD138- non-neoplastic cells was associated with CD117 expression in MM cells. Combinatorial analysis of LMP1 and CD117 stratified patients into good prognostic group LMP1+/CD117- (mean survival 4.16 ± 0.39 years) and a worst prognostic group; LMP1-/CD117+ (mean survival 1.02 ± 0.29 years). Our study showed that LMP1 expression in CD138- non-neoplastic cells of BM in MM patients confers a survival advantage.

AB - Multiple myeloma (MM) is a heterogeneous disease of the bone marrow (BM). Its association with Epstein–Barr virus (EBV) remains enigmatic. Aim of our study was to determine expression of latent membrane protein 1 (LMP1), aldehyde dehydrogenase 1 (ALDH1), CD117 and their association with 5-year survival in MM patients. Seven percent of cases expressed LMP1 in MM cells with no association with survival. Whereas, LMP1 expression in CD138- non-neoplastic cells was observed in 80% of the cases, conferring a survival advantage of 1.75 years (mean 3.75 ± 0.28, 95% CI 3.19–4.3). LMP1 in CD138- non-neoplastic cells was associated with CD117 expression in MM cells. Combinatorial analysis of LMP1 and CD117 stratified patients into good prognostic group LMP1+/CD117- (mean survival 4.16 ± 0.39 years) and a worst prognostic group; LMP1-/CD117+ (mean survival 1.02 ± 0.29 years). Our study showed that LMP1 expression in CD138- non-neoplastic cells of BM in MM patients confers a survival advantage.

KW - LMP1

KW - multiple myeloma

KW - stem cell markers

UR - http://www.scopus.com/inward/record.url?scp=85063484974&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1563697

DO - 10.1080/10428194.2018.1563697

M3 - Article

C2 - 30912465

AN - SCOPUS:85063484974

SN - 1042-8194

VL - 60

SP - 1991

EP - 2001

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 8

ER -

LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this